148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma

Knox, Susan J.; Goris, Michael L.; Trisler, Kirk; Davis, Tom A.; Liles, Tina-Marie; Fowler, Sherry; Chinn, Paul; Morena, Ron A.; Dallaire, Brian K.; Grillo-López, Antonio J; Deb, Nimisha; Becker, Mark; Marquez, Carol; Ning, Shoucheng; Levy, Ronald

doi:10.1016/0360-3016(95)97811-e

Cited by 108 publications

(146 citation statements)

References 0 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…A 67% overall response rate has been achieved in NHL patients receiving Zevalin 61 . Experience with a single dose of Bexxar in 582 patients in five clinical trials has resulted in responses lasting from three months to five and a half years.…”

Section: Resultsmentioning

confidence: 97%

“…In summary, thirteen monoclonal antibodies have been approved by the FDA at present, and two of these are radiolabelled, both for the treatment of CD20 + NHL: Bexxar, a murine IgG2a anti-CD20 mAb labelled with 131 I; and Zevalin, a murine IgG1 anti-CD20 mAb labelled with 90 Y via a BCA 61,68 . A 67% overall response rate has been achieved in NHL patients receiving Zevalin 61 .…”

Section: Resultsmentioning

confidence: 99%

“…Zevalin has been approved as part of a therapeutic regimen involving Rituxan. Phase I/II studies with Zevalin demonstrated the antitumour efficacy and safety in patients with recurrent B-cell lymphoma, and also established 'pre-treating' patients with unlabelled mAb as part of the treatment protocol 61 . Targeted radiation therapy with doses up to 50 mCi resulted in minimal nonhaematological toxicity and durable clinical responses.…”

Section: Metal-binding Charactermentioning

confidence: 99%

See 2 more Smart Citations

Antibody-targeted radiation cancer therapy

Milenic

Brady

Brechbiel

2004

Nat Rev Drug Discov

338

290

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 97%

Section: Resultsmentioning

confidence: 99%

Section: Metal-binding Charactermentioning

confidence: 99%

See 1 more Smart Citation

Antibody-targeted radiation cancer therapy

Milenic

Brady

Brechbiel

2004

Nat Rev Drug Discov

338

290

View full text Add to dashboard Cite

“…Owing to concerns about Table 1 Properties of FDA approved RIT products available for therapy in B-cell NHL Modified from (Cheson, 2003) and (Stern and Herrmann, 2005) Results from the phase I/II dose escalation trial of Y 90 ibritumomab tixuetan, given in the format that we recognize as the commercial product administered today, were published in 1999 (Witzig et al, 1999). A previous phase I/II with Y 90 -labelled ibritumomab had used ibritumomab before the therapeutic infusion and dosing levels were escalated according to a flat level of total dose of between 20 and 50 mCi, with doses below 40 mCi being found to be nonmyeloablative (Knox et al, 1996). The study of Witzig et al (1999), established that the maximum-tolerated dose was 0.4 mCi/Kg, reduced to 0.3 mCi/Kg in those with a baseline platelet count of between 100 and 149 Â 10 9 /l and replaced the unlabelled ibritumomab with rituximab 250 mg/m 2 given before the dosimetric or therapeutic infusions.…”

Section: Tositumomabmentioning

confidence: 99%

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Davies

2007

Oncogene

View full text Add to dashboard Cite

Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing -Y 90 ibritumomab tiuxetan and I 131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.

show abstract

“…16 Despite this shortcoming, 1B4M-DTPA is a component of the clinically approved Ibritumomab primarily due to practical and reproducible radiolabeling chemistry. 17 .…”

Section: Introductionmentioning

confidence: 99%

Rational Design and Generation of a Bimodal Bifunctional Ligand for Antibody-Targeted Radiation Cancer Therapy

Chong

et al. 2007

J. Med. Chem.

View full text Add to dashboard Cite

An antibody-targeted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand that can effectively hold a cytotoxic metal with clinically acceptable complexation kinetics and stability while being attached to a tumor-specific antibody. Clinical exploration of the therapeutic potential of RIT has been challenged by the absence of adequate ligand, a critical component for enhancing the efficacy of the cancer therapy. To address this deficiency, the bifunctional ligand C-NETA in a unique structural class possessing both a macrocyclic cavity and a flexible acyclic moiety was designed. The practical, reproducible, and readily scalable synthetic route to C-NETA was developed, and its potential as the chelator of 212 Bi, 213 Bi, and 177 Lu for RIT was evaluated in vitro and in vivo. C-NETA rapidly binds both Lu(III) and Bi(III), and the respective metal complexes remain extremely stable in serum for 14 days. 177 Lu-C-NETA and 205/6 Bi-C-NETA possess an excellent or acceptable in vivo biodistribution profile.

show abstract

148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma

Cited by 108 publications

References 0 publications

Antibody-targeted radiation cancer therapy

Antibody-targeted radiation cancer therapy

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Rational Design and Generation of a Bimodal Bifunctional Ligand for Antibody-Targeted Radiation Cancer Therapy

Contact Info

Product

Resources

About